Teva Pharmaceutical Industries Ltd. has announced the launch its generic version of Pataday® (olopatadine hydrochloride ophthalmic solution) 0.2% in the U.S.
Olopatadine hydrochloride ophthalmic solution 0.2% is reportedly a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Teva is reportedly working to strengthen its generics business through continued investment in complex, high-quality products.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Teva Pharmaceutical Industries Ltd.